Trade Vitrolife - VITR CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentSEK 1,000.00Overnight funding adjustmentCharges from full value of position-0.015675 %(-SEK 3.10)Trade size with leverage ~ SEK 20,000.00Money from leverage ~ $SEK 19,000.00Go to platform: -0.01568%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentSEK 1,000.00Overnight funding adjustmentCharges from full value of position-0.006547 %(-SEK 1.30)Trade size with leverage ~ SEK 20,000.00Money from leverage ~ $SEK 19,000.00Go to platform: -0.00655%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: SEK
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Sweden
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: SEK 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.015675 %
  (-SEK 3.10)

• Margin. Your investment: SEK 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.006547 %
  (-SEK 1.30)

Key Stats

• Prev. Close: 92.8
• Open: 92.4
• 1-Year Change: -32.26%
• Day's Range: 92.2 - 93.6

Trade Vitrolife - VITR

About Vitrolife AB

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vitrolife AB revenues increased 35% to SEK1.68B. Net income applicable to common stockholders increased 19% to SEK341M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share remained flat at SEK0.80. Basic Earnings per Share excluding Extraordinary Items increased from SEK2.64 to SEK2.97.

Equity composition

1999: Stock Split in the ratio 1:2. 5/2018, 5-for-1 stock split (Factor: 5).